Massachusetts Financial Services
CPRX

Massachusetts Financial Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Massachusetts Financial Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$912K Sell
36,841
-40,592
-52% -$967K ﹤0.01% 852
2025
Q4 		$1.81M Sell
77,433
-2,564
-3% -$57.1K ﹤0.01% 797
2025
Q3 		$1.58M Buy
79,997
+5,262
+7% +$108K ﹤0.01% 777
2025
Q2 		$1.62M Buy
74,735
+925
+1% +$21.8K ﹤0.01% 782
2025
Q1 		$1.79M Sell
73,810
-1,684
-2% -$37.9K ﹤0.01% 765
2024
Q4 		$1.58M Sell
75,494
-2,253
-3% -$48.4K ﹤0.01% 783
2024
Q3 		$1.55M Sell
77,747
-1,883
-2% -$34.9K ﹤0.01% 758
2024
Q2 		$1.23M Buy
79,630
+2,672
+3% +$41.6K ﹤0.01% 783
2024
Q1 		$1.23M Sell
76,958
-170
-0.2% -$2.56K ﹤0.01% 771
2023
Q4 		$1.3M Sell
77,128
-2,435
-3% -$33.3K ﹤0.01% 756
2023
Q3 		$930K Sell
79,563
-3,049
-4% -$40.8K ﹤0.01% 768
2023
Q2 		$1.11M Sell
82,612
-1,945
-2% -$28K ﹤0.01% 746
2023
Q1 		$1.4M Buy
+84,557
New +$1.39M ﹤0.01% 733

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Massachusetts Financial Services's CPRX Position: Q1 2026 in Review

Massachusetts Financial Services reduced its Catalyst Pharmaceutical (CPRX) stake by 52% in Q1 2026, selling an estimated $967K and leaving 36,841 shares worth $912K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Massachusetts Financial Services first reported a position in CPRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.81M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Massachusetts Financial Services held 36,841 shares of Catalyst Pharmaceutical worth $912K as of Q1 2026.
  • Massachusetts Financial Services sold 40,592 Catalyst Pharmaceutical shares in Q1 2026, an estimated $967K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q1 2026, its #852 holding.
  • Massachusetts Financial Services first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 13 quarters since.
  • Massachusetts Financial Services's Catalyst Pharmaceutical position peaked at $1.81M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Massachusetts Financial Services's 13F filing for Q1 2026, filed 14 May 2026.